Immatics (NASDAQ: IMTX)
$5.96
(0.3%)
$0.02
Price as of June 11, 2025, 4:00 p.m. ET
Immatics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immatics Company Info
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
News & Analysis
Featured Article
Why Immatics Stock Is Soaring Today
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.
Keith Speights | May 2, 2023
Featured Article
Why Immatics Stock Is Soaring Today
Investors liked the company's latest clinical update.
Prosper Junior Bakiny | Mar 17, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.